Corvus Pharmaceuticals, Inc.
CRVS
Price:
$4.69
Market Cap:
$301.37M
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for p...[Read more]
Industry
Biotechnology
IPO Date
2016-03-23
Stock Exchange
NASDAQ
Ticker
CRVS
PE Ratio
[-4.74]
ROE
[-167.55%]
Current Ratio
[0.92]
Dividend Yield
[0%]
Enterprise Value
[297.04M]
Dividend History
The ROE as of December 2024 (TTM) for Corvus Pharmaceuticals, Inc. (CRVS) is -167.55%
According to Corvus Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -167.55%. This represents a change of 82.76% compared to the average of -91.68% of the last 4 quarters.
Corvus Pharmaceuticals, Inc. (CRVS) Historical ROE (quarterly & annually)
How has CRVS ROE performed in the past?
The mean historical ROE of Corvus Pharmaceuticals, Inc. over the last ten years is -19.09%. The current -167.55% ROE has changed 777.61% with respect to the historical average. Over the past ten years (40 quarters), CRVS's ROE was at its highest in in the December 2020 quarter at 37.90%. The ROE was at its lowest in in the September 2024 quarter at -324.10%.
Average
-19.09%
Median
-40.93%
Minimum
-89.19%
Maximum
110.46%
Corvus Pharmaceuticals, Inc. (CRVS) ROE by Quarter and Year
Discovering the peaks and valleys of Corvus Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 488.13%
Maximum Annual ROE = 110.46%
Minimum Annual Increase = -127.19%
Minimum Annual ROE = -89.19%
| Year | ROE | Change |
|---|---|---|
| 2023 | -69.87% | -21.66% |
| 2022 | -89.19% | 126.86% |
| 2021 | -39.32% | 488.13% |
| 2020 | -6.68% | -89.13% |
| 2019 | -61.52% | 44.61% |
| 2018 | -42.54% | -35.16% |
| 2017 | -65.61% | 139.55% |
| 2016 | -27.39% | -127.19% |
| 2015 | 100.75% | -8.79% |
Corvus Pharmaceuticals, Inc. (CRVS) Average ROE
How has CRVS ROE performed in the past?
The current ROE of Corvus Pharmaceuticals, Inc. (CRVS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-66.13%
5-year avg
-53.32%
10-year avg
-19.09%
Corvus Pharmaceuticals, Inc. (CRVS) ROE vs. Peers
How is CRVS’s ROE compared to its peers?
Corvus Pharmaceuticals, Inc.’s ROE is greater than Mereo BioPharma Group plc (-69.11%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than PDS Biotechnology Corporation (-139.57%), greater than Inozyme Pharma, Inc. (-88.42%), greater than HOOKIPA Pharma Inc. (-49.25%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Acumen Pharmaceuticals, Inc. (-32.99%),
| Company | ROE | Market cap |
|---|---|---|
| -69.11% | $516.04M | |
| -32.76% | $498.59M | |
| -139.57% | $62.10M | |
| -88.42% | $190.15M | |
| -49.25% | $19.21M | |
| -32.51% | $106.61M | |
| -22.40% | $1.27B | |
| -32.99% | $106.94M |
Build a custom stock screener for Corvus Pharmaceuticals, Inc. (CRVS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Corvus Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Corvus Pharmaceuticals, Inc. (CRVS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Corvus Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Corvus Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Corvus Pharmaceuticals, Inc. (CRVS)?
What is the highest ROE for Corvus Pharmaceuticals, Inc. (CRVS)?
What is the 3-year average ROE for Corvus Pharmaceuticals, Inc. (CRVS)?
What is the 5-year average ROE for Corvus Pharmaceuticals, Inc. (CRVS)?
How does the current ROE for Corvus Pharmaceuticals, Inc. (CRVS) compare to its historical average?